

DAFTAR PUSTAKA

1. International Diabetes Federation. IDF Diabetes Atlas Ninth Edition 2019. IDF; 2019.
2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Urwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract.* 2019;157:107843.
3. Soelistijo S, Novida H, Rudijanto A, Soewondo P, Suastika k, Manaf A, et al. Konsensus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe2 Di Indonesia 2015. PB Perkeni; 2015.
4. Müller-Wieland PD, Nauck M, Petersmann A, Freckmann G, Heinemann L, Schleicher E. Definition, Classification and Diagnosis of Diabetes Mellitus. *Diabetologie.* 2019;15(2):128-134.
5. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990-2010. *N Engl J Med.* 2014;370(16):1514-1523.
6. Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR, Aguilar RB. The time is right for a new classification system for diabetes: Rationale and implications of the β -cell-centric classification schema. *Diabetes Care.* 2016;39(2):179-186.
7. Internatinal Diabetes Federation. Diabetes and cardiovascular disease. IDF; 2016.
8. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. *Diabetologia.* 2019;62(1):3-16.
9. Segel JE. Cost-of-Illness Studies — A Primer. 2015;(March).
10. Idzior B, Waluś M. Is now the time for probiotics in diabetes management? *Pol Arch Med Wewn.* 2015;125(11):797-798.
11. Akbari V, Hendijani F. Effects of probiotic supplementation in patients with type 2 diabetes: Systematic review and meta-analysis. *Nutr Rev.* 2016;74(12):774-784.
12. He C, Shan Y, Song W. Targeting gut microbiota as a possible therapy for diabetes. *Nutr Res.* 2015;35(5):361-367.
13. Azad MAK, Sarker M, Li T, Yin J. Probiotic Species in the Modulation of Gut Microbiota: An Overview. *Biomed Res Int.* 2018; 2018.

14. Wu X, C Ma L, Han M, Nawaz F, Gao X, Zhang P, et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. *Curr Microbiol.* 2010;61(1):69-78.
15. Sun Z, Sun X, Li J. Using probiotics for type 2 diabetes mellitus intervention: Advances, questions, and potential. *Crit Rev Food Sci Nutr.* 2020;60(4):670-683.
16. Food and Agriculture Organization. Guidelines for the Evaluation of Probiotics in Food; Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food; FAO: 2002.
17. Rad A H, S. Abbasalizadeh S, Vazifekhah F, Abbasalizadeh T, Hassanalilou P, Bastani HS, et al. The future of diabetes management by healthy probiotic microorganisms. *Diabetes Rev.* 2017;6(13):582-589.
18. Van Olden C, Groen AK, Nieuwdorp M. Role of Intestinal Microbiome in Lipid and Glucose Metabolism in Diabetes Mellitus. *Clin Ther.* 2015;37(6):1172-1177.
19. Hampe CS, Roth CL. Probiotic strains and mechanistic insights for the treatment of type 2 diabetes. *Endocrine.* 2017;58(2):207-227.
20. Zhang Z, Lv J, Pan L, Zhang Y. Roles and applications of probiotic Lactobacillus strains. *Appl Microbiol Biotechnol.* 2018;102(19):8135-8143.
21. Dustin D, Heeney, Mélanie G Gareau and MLM. Intestinal Lactobacillus in health and disease, a driver or just along for the ride?. *Curr Opin Biotechnol.* 2018;49(1):140-147.
22. Panwar H, Calderwood D, Grant IR, Grover S, Green BD. Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential. *Eur J Nutr.* 2014;53(7):1465-1474.
23. Toshimitsu T, Mochizuki J, Ikegami S, Itou H. Identification of a Lactobacillus plantarum strain that ameliorates chronic inflammation and metabolic disorders in obese and type 2 diabetic mice. *J Dairy Sci.* 2016;99(2):933-946.
24. Dang F, Jiang Y, Pan R, Zhou Y, Wu S, Wang R, et al. Administration of Lactobacillus paracasei ameliorates type 2 diabetes in mice. *Food Funct.* 2018;9(7):3630-3639.
25. Khalili L, Alipour B, Jafar-Abadi MA, Faraji I, Hassanalilou T, Abbasi MM, et al. The effects of lactobacillus casei on glycemic response, serum sirtuin1 and fetuin-A levels in patients with type 2 diabetes mellitus: A randomized controlled trial. *Iran Biomed J.* 2019;23(1):68-77.
26. Feizollahzadeh S, Ghiasvand R, Rezaei A, Khanahmad H, sadeghi A,

- Hariri M. Effect of Probiotic Soy Milk on Serum Levels of Adiponectin, Inflammatory Mediators, Lipid Profile, and Fasting Blood Glucose Among Patients with Type II Diabetes Mellitus. *Probiotics Antimicrob Proteins*. 2017;9(1):41-47.
27. Miraghajani M, Dehsoukhteh SS, Rafie N, Hamedani SG, Sabihi S, Ghiasvand R. Potential mechanisms linking probiotics to diabetes: a narrative review of the literature. *Sao Paulo Med J*. 2017;135(2):169-178.
 28. Kasińska MA, Drzewoski J. Effectiveness of probiotics in type 2 diabetes: A meta-analysis. *Pol Arch Med Wewn*. 2015;125(11):803-813.
 29. DeFronzo RA. *Pathogenesis of Type 2 Diabetes Mellitus*. San Antonio: Springer International Publishing; 2017.
 30. Dorland. *Kamus Saku Kedokteran Dorland*. 28th ed. Singapore: elsevier; 2011.
 31. National Center for Biotechnology Information (NCBI). Lactobacillus. MesH database. <https://www.ncbi.nlm.nih.gov/mesh/68003920>.
 32. National Center for Biotechnology Information (NCBI). Type 2 Diabetes Mellitus. MesH database. <https://www.ncbi.nlm.nih.gov/mesh/68003924>. Published 2005.
 33. National Center for Biotechnology Information (NCBI). 2015. In Vitro Techniques. MesH database. <https://www.ncbi.nlm.nih.gov/mesh/68066298>. -Diakses Agustus 2020
 34. National Center for Biotechnology Information (NCBI). 2008. Review. MesH database. <https://www.ncbi.nlm.nih.gov/mesh/68016454>. -Diakses Agustus 2020
 35. National Center for Biotechnology Information (NCBI). 2008. Clinical Trial. MesH database. <https://www.ncbi.nlm.nih.gov/mesh/68016430>. -Diakses Agustus 2020
 36. National Center for Biotechnology Information (NCBI). 2018. Gastrointestinal Microbiome. MesH database. <https://www.ncbi.nlm.nih.gov/mesh/?term=gastrointestinal+microbiome>. -Diakses Agustus 2020
 37. National Center for Biotechnology Information (NCBI). 2020. Fermented Foods And Beverages. MesH database. <https://www.ncbi.nlm.nih.gov/mesh/2023313>. -Diakses Agustus 2020
 38. National Center for Biotechnology Information (NCBI). Rats. 2006. MesH database. <https://www.ncbi.nlm.nih.gov/mesh/68051381>. -Diakses Agustus 2020

39. National Center for Biotechnology Information (NCBI). 2006. Mice. MesH database. <https://www.ncbi.nlm.nih.gov/mesh/68051379>-Diakses Agustus 2020
40. National Center for Biotechnology Information (NCBI). 2008. Randomized Controlled Trial. MesH database. <https://www.ncbi.nlm.nih.gov/mesh/68016449>-Diakses Agustus 2020
41. CEBM. 2018. Critical Appraisal Tools. CEBM. <https://www.cebm.net/wp-content/uploads/2018/11/RCT.pdf>. -Diakses Agustus 2020
42. Hooijmans CR, Rovers MM, De Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. *BMC Med Res Methodol*. 2014;14(1):1-9.
43. Zeng Z, Yuan Q, Yu R, Zhang J, Ma H, Chen S. Ameliorative Effects of Probiotic *Lactobacillus paracasei* NL41 on Insulin Sensitivity, Oxidative Stress, and Beta-Cell Function in a Type 2 Diabetes Mellitus Rat Model. *Mol Nutr Food Res*. 2019;63(22):1-9.
44. Tian P, Li B, He C, Song W, Hou A, Tian S, et al. Antidiabetic (type 2) effects of *Lactobacillus* G15 and Q14 in rats through regulation of intestinal permeability and microbiota. *Food Funct*. 2016;7(9):3789-3797.
45. Honda K, Moto M, Uchida N, He F, Hashizume N. Anti-diabetic effects of lactic acid bacteria in normal and type 2 diabetic mice. *J Clin Biochem Nutr*. 2012;51(2):96-101.
46. Chen P, Zhang Q, Dang H, Liu X, Tian F, Zhao J, et al. Antidiabetic effect of *Lactobacillus casei* CCFM0412 on mice with type 2 diabetes induced by a high-fat diet and streptozotocin. *Nutrition*. 2014;30(9):1061-1068.
47. Li X, Wang E, Yin B, Fang D, Chen P, Wang G, et al. Effects of *Lactobacillus casei* CCFM419 on insulin resistance and gut microbiota in type 2 diabetic mice. *Benef Microbes*. 2017;8(3):421-432.
48. Chen X, Tan F, Yi R, Mu J, Zhao X, Yang Z. Effects of *Lactobacillus* on mice with diabetes induced by high-fat diet with streptozotocin (STZ). *Appl Sci*. 2018;8(8):1-14.
49. Toshimitsu T, Ozaki S, Mochizuki J, Furuichi K, Asami Y. Effects of *Lactobacillus plantarum* strain OLL2712 culture conditions on the anti-inflammatory activities for murine immune cells and obese and type 2 diabetic mice. *Appl Environ Microbiol*. 2017;83(7):1-11.
50. Yan F, Li N, Shi J, Li H, Yue Y, Jiao W, et al. *Lactobacillus acidophilus* alleviates type 2 diabetes by regulating hepatic glucose, lipid metabolism and gut microbiota in mice. *Food Funct*. 2019;10(9):5804-5815.
51. Wang G, Li X, Zhao J, Zhang H, Chen W. *Lactobacillus casei* CCFM419

attenuates type 2 diabetes via a gut microbiota dependent mechanism. *Food Funct.* 2017;8(9):3155-3164.

52. Farida E, Nuraida L, Giriwono PE, Jenie BSL. Lactobacillus rhamnosus Reduces Blood Glucose Level through Downregulation of Gluconeogenesis Gene Expression in Streptozotocin-Induced Diabetic Rats. *Int J Food Sci.* 2020;2020.
53. Chen P, Zhang Q, Dang H, Liu X, Tian F, Zhao J, et al. Oral administration of Lactobacillus rhamnosus CCFM0528 improves glucose tolerance and cytokine secretion in high-fat-fed, streptozotocin-induced type 2 diabetic mice. *J Funct Foods.* 2014;10:318-326.
54. Li KK, Tian PJ, Wang SD, Lei P, Qu L, Huang JP, et al. Targeting gut microbiota: Lactobacillus alleviated type 2 diabetes via inhibiting LPS secretion and activating GPR43 pathway. *J Funct Foods.* 2017;38:561-570.
55. Yan F, Li N, Yue Y, Wang C, Zhao L, Evvie SE, et al. Screening for Potential Novel Probiotics With Dipeptidyl Peptidase IV-Inhibiting Activity for Type 2 Diabetes Attenuation in vitro and in vivo. *Front Microbiol.* 2020;10.
56. Memarrast F, Ghafouri-Fard S, Kolivand S, et al. Comparative evaluation of probiotics effects on plasma glucose, lipid, and insulin levels in streptozotocin-induced diabetic rats. *Diabetes Metab Res Rev.* 2017;33(7).
57. Qu L, Ren J, Huang L, Pang b, Liu X, Liu X, et al. Antidiabetic Effects of Lactobacillus casei Fermented Yogurt through Reshaping Gut Microbiota Structure in Type 2 Diabetic Rats. *J Agric Food Chem.* 2018;66(48):12696-12705.
58. Li C, Ding Q, Nie SP, Zhang YS, Xiong T, Xie MY. Carrot juice fermented with lactobacillus plantarum NCU116 ameliorates type 2 diabetes in rats. *J Agric Food Chem.* 2014;62(49):11884-11891.
59. Huang YC, Wu BH, Chu YL, Chang WC, Wu MC. Effects of tempeh fermentation with lactobacillus plantarum and rhizopus oligosporus on streptozotocin-induced type II diabetes mellitus in rats. *Nutrients.* 2018;10(9).
60. Singh S, Sharma RK, Malhotra S, Pothuraju R, Shandilya UK. Lactobacillus rhamnosus NCDC17 ameliorates type-2 diabetes by improving gut function, oxidative stress and inflammation in high-fat-diet fed and streptozotocintreated rats. *Benef Microbes.* 2017;8(2):243-255.
61. Hartajanie L, Fatimah-Muis S, Heri-Nugroho Hs K, Riwanto I, Sulchan M. Probiotics Fermented Bitter Melon Juice as Promising Complementary Agent for Diabetes Type 2: Study on Animal Model. *J Nutr Metab.* 2020;2020.

62. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg MG, Moller K, Svendsen KD, et al. Effects of *Lactobacillus acidophilus* NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. *Br J Nutr.* 2010;104(12):1831-1838.
63. Mobini R, Tremaroli V, Ståhlman M, Karlsson F, Levin M, Ljungberg M, et al. Metabolic effects of *Lactobacillus reuteri* DSM 17938 in people with type 2 diabetes: A randomized controlled trial. *Diabetes, Obes Metab.* 2017;19(4):579-589.
64. Khalili L, Alipour B, Asghari Jafarabadi M, Hassanalilou T, Mesgari Abbasi M, Faraji I. Probiotic assisted weight management as a main factor for glycemic control in patients with type 2 diabetes: A randomized controlled trial. *Diabetol Metab Syndr.* 2019;11(1):1-9.
65. Hsieh MC, Tsai WH, Jheng YP, Su SL, Wang SY, Lin CC, et al. The beneficial effects of *Lactobacillus reuteri* ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial. *Sci Rep.* 2018;8(1):1-11.
66. Mazloom Z, Yousefinejad A, Dabbaghmanesh MH. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: A clinical trial. *Iran J Med Sci.* 2013;38(1):38-43.
67. Asemi Z, Alizadeh SA, Ahmad K, Goli M, Esmailzadeh A. Effects of beta-carotene fortified synbiotic food on metabolic control of patients with type 2 diabetes mellitus: A double-blind randomized cross-over controlled clinical trial. *Clin Nutr.* 2016;35(4):819-825. d
68. Tajadadi-Ebrahimi M, Bahmani F, Shakeri H, Hadaegh H, Hijijafari M, Abedi F, et al. Effects of daily consumption of synbiotic bread on insulin metabolism and serum high-sensitivity c-reactive protein among diabetic patients: A double-blind, randomized, controlled clinical trial. *Ann Nutr Metab.* 2014;65(1):34-41.
69. Asemi Z, Khorrami-Rad A, Alizadeh SA, Shakeri H, Esmailzadeh A. Effects of synbiotic food consumption on metabolic status of diabetic patients: A double-blind randomized cross-over controlled clinical trial. *Clin Nutr.* 2014;33(2):198-203.
70. Sato J, Kanazawa A, Azuma K, Ikeda F, Goto H, Komiya K et al. Probiotic reduces bacterial translocation in type 2 diabetes mellitus: A randomised controlled study. *Sci Rep.* 2017;7(1):1-10.
71. Toshimitsu T, Mochizuki J, Ikegami S, Ito H. Identification of a *Lactobacillus plantarum* strain that ameliorates chronic inflammation and metabolic disorders in obese and type 2 diabetic mice. *J Dairy Sci.* 2016;99(2):933-946.

72. Li X, Wang N, Yin B, et al. Effects of *Lactobacillus plantarum* CCFM0236 on hyperglycaemia and insulin resistance in high-fat and streptozotocin-induced type 2 diabetic mice. *J Appl Microbiol.* 2016;121(6):1727-1736.
73. Toshimitsu T, Ozaki S, Mochizuki J, Furuichi K, Asami K. crossm Effects of *Lactobacillus plantarum* Strain OLL2712 Culture Conditions on the Anti- inflammatory Activities for Murine. *Appl Environ Microbiol.* 2017;83(7):1-11.
74. Dang F, Jiang Y, Pan R, Zhou Y, Wu S, Wang R, et al. Administration of *Lactobacillus paracasei* ameliorates type 2 diabetes in mice. *Food Funct.* 2018;9(7):3630-3639.
75. Aronsson L, Huang Y, Parini P, Andre MK, Hakansson J, Gustafsson JA, et al. Decreased fat storage by *Lactobacillus paracasei* is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). *PLoS One.* 2010;5(9):1-7.
76. Rodes L, Khan A, Paul A, Charley MC, Marinescu D, Duchesneau C, et al. Effect of probiotics *Lactobacillus* and *Bifidobacterium* on gut-derived lipopolysaccharides and inflammatory cytokines: An in vitro study using a human colonic microbiota model. *J Microbiol Biotechnol.* 2013;23(4):518-526.
77. Zhang Z, Liang X, Lv Y, Yi H, Chen Y, Bai L, et al. Evaluation of probiotics for improving and regulation metabolism relevant to type 2 diabetes in vitro. *J Funct Foods.* 2020;64.
78. Li B, Du P, Smith EE, Wang S, Jiao Y, Guo L, et al. In vitro and in vivo evaluation of an exopolysaccharide produced by *Lactobacillus helveticus* KLDS1.8701 for the alleviative effect on oxidative stress. *Food Funct.* 2019;10(3):1707-1717.
79. Cai T, Wu H, Qin J, Qiao J, Yang Y, Wu Y, et al. In vitro evaluation by PCA and AHP of potential antidiabetic properties of lactic acid bacteria isolated from traditional fermented food. *Lwt.* 2019;115.
80. Sun L, Tian W, Guo X, Zhang Y, Li X, Tian X, et al. *Lactobacillus gasseri* JM1 with potential probiotic characteristics alleviates inflammatory response by activating the PI3K/Akt signaling pathway in vitro. *J Dairy Sci.* 2020; 103(9):7851-7864
81. Heeney DD, Zhai Z, Bendiks Z, Barouei J, Martinic A, Slupsky C, et al. *Lactobacillus plantarum* bacteriocin is associated with intestinal and systemic improvements in diet-induced obese mice and maintains epithelial barrier integrity in vitro. *Gut Microbes.* 2019;10(3):382-397.
82. Lee E, Jung SR, Lee SY, Lee NK, Paik HD, Lim S II. *Lactobacillus plantarum* strain In4 attenuates diet-induced obesity, insulin resistance, and

changes in hepatic mRNA levels associated with glucose and lipid metabolism. *Nutrients*. 2018;10(5).

83. Wei SH, Chen YP, Chen MJ. Selecting probiotics with the abilities of enhancing GLP-1 to mitigate the progression of type 1 diabetes in vitro and in vivo. *J Funct Foods*. 2015;18(5):473-486.
84. Huang Z, Lin F, Zhu X, Zhang C, Jiang M, Lu Z. An exopolysaccharide from *Lactobacillus plantarum* H31 in pickled cabbage inhibits pancreas α -amylase and regulating metabolic markers in HepG2 cells by AMPK/PI3K/Akt pathway. *Int J Biol Macromol*. 2020;143:775-784.
85. Zeng Z, Luo J, Zuo F, Zhang Y, Ma H, Chen S. Screening for potential novel probiotic *Lactobacillus* strains based on high dipeptidyl peptidase IV and α -glucosidase inhibitory activity. *J Funct Foods*. 2016;20(17):486-495.
86. Brown K, Godovannyi A, Ma C, Zhang YQ, Ahmadi-Vand Z, Dai C, et al. Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. *ISME J*. 2016;10(2):321-332.
87. Khodabandehloo H, Gorgani-Firuzjaee S, Panahi G, Meshkani R. Molecular and cellular mechanisms linking inflammation to insulin resistance and β -cell dysfunction. *Transl Res*. 2016;167(1):228-256.
88. Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: Review of the underlying molecular mechanisms. *J Cell Physiol*. 2019;234(6):8152-8161.
89. Mohamed J, Nazratun Nafizah AH, Zariyantey AH, Budin SB. Mechanisms of diabetes-induced liver damage: The role of oxidative stress and inflammation. *Sultan Qaboos Univ Med J*. 2016;16(2):e132-e141.
90. Kumar V, Abul K A, Aster C J. *Robbin Basic Pathology*. 9th ed. Philadelphia: elsevier; 2013.
91. Burgos-Morón E, Abad-Jiménez Z, Marañón AM, Iannantuoni F, Escibano-Lopez I, Rocha M, et al. Relationship Between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues. *J Clin Med*. 2019;8(9):1385.
92. Abdelazez A, Abdelmotaal H, Evivie SE, Melak S, Jia FF, Khoso MH, et al. Screening potential probiotic characteristics of *Lactobacillus brevis* strains in vitro and intervention effect on type i diabetes in vivo. *Biomed Res Int*. 2018;2018.
93. Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. *Nat Rev Endocrinol*. 2017; 13(10): 572–587.

94. Titchenell PM, Lazar MA, Birnbaum MJ. Unraveling the Regulation of Hepatic Metabolism by Insulin. *Trends Endocrinol Metab.* 2017;28(7):497-
95. Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. *Int J Mol Sci.* 2017;18(6).
96. E Hall J, C Guyton A. Guyton Dan Hall Buku Ajar Fisiologi Kedokteran. Philadelphia: elselvier; 2011.
97. FDA. GRAS Notices. <https://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices-Diakses> Mei 2020
98. Markowiak P, Ślizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. *Nutrients.* 2017;9(9).
99. Roselino MN, Pauly-Silveira ND, Cavallini DCU, Celiberto LS, Pinto RA, Vendramini RC, et al. A potential synbiotic product improves the lipid profile of diabetic rats. *Lipids Health Dis.* 2012;11:1-9.

